Aytu BioPharma, Inc. filings document a Nasdaq-listed pharmaceutical issuer with common stock trading under AYTU and a business centered on EXXUA, ADHD treatments, and other prescription products. Form 8-K reports furnish quarterly and annual operating results, Regulation FD investor materials, and material agreements affecting the company's financing and capital structure.
The filing record also includes definitive proxy disclosures covering board matters, executive compensation, equity awards, and shareholder voting items. Other 8-K disclosures address loan and security agreement amendments with Aytu operating subsidiaries, warrant-related accounting and stockholder-approval language, and classification issues affecting reported liabilities or equity.
Aytu BioPharma (AYTU) set its 2026 annual meeting for December 10, 2025 at 10:00 a.m. MT in Denver. Stockholders of record at the close of business on October 13, 2025 may vote; 10,188,208 shares of common stock were outstanding and entitled to vote. A quorum requires at least one-third of eligible shares.
Stockholders will vote to elect five directors, ratify Grant Thornton as independent auditor for the fiscal year ending June 30, 2026, and approve, on a non-binding advisory basis, 2026 executive compensation. The Board recommends voting FOR all items. Four of five directors are independent under Nasdaq rules; John A. Donofrio, Jr. serves as Chairman.
Audit fees were $849,000 in fiscal 2025 versus $1,018,000 in fiscal 2024. The Board met 12 times in fiscal 2025; the Audit Committee met six times and the Compensation Committee once. Effective July 1, 2025, non-employee director compensation includes cash retainers and annual grants of 10,000 restricted shares or RSUs. In October 2025, equity awards were granted to executives, including 22,500 restricted shares to the CEO, 17,500 to the CFO, and 12,500 each to the CBO and CCO, vesting over three years.
AYTU BioPharma (AYTU) director filed a Form 5 reporting annual changes in beneficial ownership for the fiscal year ended 06/30/2025.
The filing lists 21,152 common shares held directly and 50 common shares held indirectly through Alpha Venture Capital Management, LLC. It also notes historical transactions: a purchase of 10,000 shares on 11/18/2020 and a sale of 209 shares on 12/30/2020. After the 10:1 reverse split on 12/10/2020, the 11/18/2020 purchase price equated to $9.23 per share, with $1,929.07 attributed to 209 shares, and the 12/30/2020 sale totaled $1,256.09. The filing states the reporting person did not realize any profit in connection with this short-swing purchase and sale.
The direct holdings include 10,000 restricted shares granted on 10/03/2025. A remark notes a correction to totals previously reported on a Form 4 filed on 04/16/2021.
Officer grant and ownership change: The Chief Commercial Officer received a grant of 12,500 restricted shares of common stock that vest over time, increasing his beneficial ownership to 36,102 shares. The award was issued at a price of $0, indicating a stock-based compensation grant rather than a cash purchase. One-third of the restricted shares vest on 10/03/2026, with the remaining shares vesting in eight equal quarterly installments beginning 01/03/2027.
This transaction is a non-derivative, officer-level compensation event that aligns the officer's interests with shareholders through time-based vesting. The restricted nature of the shares means transfer or sale will be limited until vesting occurs.
Reporting person: Jarrett Disbrow, Chief Business Officer and officer of AYTU BioPharma, Inc. (AYTU), reported equity grants on 10/03/2025. The filing shows two awards of restricted common stock issued at $0 per share: 19,606 shares granted as fully vested restricted stock in lieu of an annual cash bonus, and 12,500 shares granted as time‑based restricted stock.
The newly reported grants raise the reporting person’s total beneficial ownership to 61,568 shares. The time‑based award vests one‑third on 10/03/2026 and the remainder in eight equal quarterly installments beginning 01/03/2027
AYTU Biopharma (AYTU) Chief Financial Officer Ryan J. Selhorn reported two grants of restricted common stock on 10/03/2025. He received 16,243 fully vested shares paid in lieu of cash for his annual bonus and an additional 17,500 restricted shares that vest over time: 1/3 on 10/03/2026 and the remainder in eight equal quarterly installments beginning 01/03/2027. The grants were reported with a $0 purchase price, and following these transactions Mr. Selhorn beneficially owned 49,743 shares in total after the awards. The filing is signed by Mr. Selhorn on 10/07/2025.
Insider filing summary: The Form 4 shows that Joshua R. Disbrow, CEO and director of AYTU BioPharma (AYTU), received restricted common stock on 10/03/2025. He was granted 31,446 shares as fully vested restricted stock in lieu of his annual bonus and an additional 22,500 restricted shares that vest over time. After these grants his reported beneficial ownership rose to 207,203 shares.
The 22,500-share award vests 1/3 on 10/03/2026 with the remainder vesting in eight equal quarterly installments beginning 01/03/2027. Both grants had a reported price of $0, indicating they were awards rather than market purchases. The filing is signed by an attorney-in-fact on 10/07/2025.
Vivian H. Liu, a Director of AYTU BIOPHARMA, INC (AYTU), reported a restricted stock grant of $0 price common stock on 10/03/2025. The filing shows 10,000 shares were granted and will vest on 10/03/2026. After the grant Ms. Liu beneficially owns 19,825 shares. The transaction is reported on a Form 4 and was signed by an attorney-in-fact on 10/07/2025. The award is described as restricted stock with a one-year vesting date; no cash purchase price was paid for the granted shares.
Reporting person: Abhinav Jain, a director of AYTU BIOPHARMA, INC. (AYTU), reported a grant of 10,000 restricted shares on 10/03/2025. The restricted shares carry a vesting condition that they vest on 10/03/2026. The filing shows 19,500 shares beneficially owned by the reporting person after the transaction. The transaction is recorded as a non-derivative acquisition at a $0 price, consistent with a restricted stock grant. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 10/07/2025.
Carl C. Dockery, a director of AYTU BioPharma, Inc. (AYTU), reported the grant of 10,000 restricted shares on 10/03/2025. The award carries an exercise price of $0 and is scheduled to vest on 10/03/2026. After this grant, Mr. Dockery beneficially owns 20,440 shares in total. The Form 4 was signed by an attorney-in-fact on 10/07/2025. The filing indicates these are non‑derivative restricted stock awards rather than open-market purchases, which affects the timing of when the shares become tradable.